Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05424380
Other study ID # 209809
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date September 20, 2022
Est. completion date March 4, 2024

Study information

Verified date January 2024
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, open label, two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML or HR-MDS.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 18
Est. completion date March 4, 2024
Est. primary completion date March 4, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Participants must be =18 years of age and =75 years of age at the time of signing the informed consent for dose escalation and >18 years of age at the time of signing the informed consent for the dose expansion. - Participants must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. - Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Participants with AML/HR MDS are eligible for participation in Part 1 and Part 2 if they have: 1. A diagnosis of AML according to the World Health Organization 2016 criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic options. 2. Have high-risk or high/very high by Revised International Prognostic Scoring System (IPSS-R) for MDS (restricted to Part 1) that has relapsed after or been refractory to prior therapy with hypomethylating agent. - Participants with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed if: No clinical signs or symptoms of graft versus host disease (other than Grade 1 GVHD (<25% skin surface affected) and the participant is off all systemic immunosuppression. (Note: topical steroids for G1 skin GVHD are permitted on study) - Participants must agree to abide by the gender specific contraceptive requirements below: Female participants are eligible to participate if they are not either pregnant or breastfeeding, and at least one of the following conditions applies: 1. Is not a woman of childbearing potential (WOCBP), or 2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), The effectiveness of the contraceptive method will be evaluated by the investigator in relationship to the first dose of study treatment. Exclusion Criteria: - Diagnosis of acute promyelocytic leukemia (APML or t(15;17) PML-RARA fusion). Patients with biphenotypic disease are excluded. - Active central nervous system (CNS) involvement or disorder; and well controlled with ongoing treatment - Participants with Immediate life-threatening, severe complications of leukemia (sepsis, hemorrhage). - Participants with extramedullary disease as the sole site of AML - Participants with active severe or uncontrolled infection, - Participants with active autoimmune disease that has required systemic disease modifying or immunosuppressive treatment within the last 2 years. - Participants with concurrent medical condition requiring the use of systemic immunosuppressive treatment within 28 days before the first dose of study treatment. - Participants with history of vasculitis at any time prior to study treatment. - Participant with a history of other malignancies less than 2 years prior to study entry, - Participants with QT interval corrected using Fridericia's formula (QTcF) >450 millisecond (msec) for male participants, >470 msec for female participants, or >480 msec for participants with bundle branch block. - Participants with recent history of allergen desensitization therapy within 4 weeks of starting study treatment. - Participants with history or evidence of cardiovascular (CV) risk history of immune myocarditis or pericarditis. - Participants with prior STING therapy. - Participants with prior solid organ transplantation. - Participants with recent prior therapy defined as follows: any non-monoclonal anti-cancer therapy within 14 days or 5 half-lives, whichever is longer, prior to start of study treatment; prior therapy with biological agents (including monoclonal antibodies) within 28 days prior to start of study treatment; any radiotherapy or major surgery within 14 days prior to start of study treatment; currently receiving investigational therapy in a clinical trial - Participants with immune-related toxicity related to prior treatment that has not resolved to Grade =1 (except alopecia, hearing loss or Grade =2 neuropathy or endocrinopathy managed with replacement therapy).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GSK3745417
GSK3745417 will be administered

Locations

Country Name City State
Canada GSK Investigational Site Toronto Ontario
Germany GSK Investigational Site Dresden Sachsen
Germany GSK Investigational Site Halle Sachsen-Anhalt
Germany GSK Investigational Site Leipzig Sachsen
Italy GSK Investigational Site Meldola
Italy GSK Investigational Site Perugia
Italy GSK Investigational Site Roma
Netherlands GSK Investigational Site Rotterdam
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Valencia

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Canada,  Germany,  Italy,  Netherlands,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Number of participants with Adverse Events (AEs) and number of participants per severity grade of AE in total population Severity for each AE will be reported during the study and will assign a grade according to the National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v5.0. Up to 36 weeks
Primary Part 1: Number of participants with Serious Adverse Events (SAEs) and number of participants per severity grade of SAE in total population Severity for each SAE will be reported during the study and will assign a grade according to the NCI-CTCAE v5.0. Up to 49 weeks
Primary Part 1: Number of participants with Dose limiting toxicities (DLT) and number of participants per severity grade of DLT An AE will be considered a DLT if the investigator considers it to be clinically relevant and attributed (definitely, probably, or possibly) to the study intervention and meets at least 1 of the DLT criteria. Severity for DLT will be reported according to the NCI-CTCAE v5.0. Up to 4 weeks
Primary Part 1: Number of participants with withdrawals due to AEs Up to 36 weeks
Primary Part 2: Overall response rate (ORR) after the daily dosing induction period of GSK3745417 ORR is defined as the percentage of participants with a complete remission (CR), CR with incomplete platelet recovery (CRp), CR with incomplete count recovery (CRi), or a partial remission (PR) as per response criteria for AML and HR MDS respectively. Up to 12 weeks
Primary Part 2: Number of participants with AEs and number of participants per severity grade of AE in total population during maintenance dosing Severity for each AE will be reported during the study and will assign a grade according to the NCI-CTCAE v5.0. Up to 36 weeks
Primary Part 2: Number of participants with SAEs and number of participants per severity grade of SAE in total population during maintenance dosing Severity for each SAE will be reported during the study and will assign a grade according to the NCI-CTCAE v5.0. Up to 49 weeks
Primary Part 2: Number of participants with DLT and number of participants per severity grade of DLT during maintenance dosing An AE will be considered a DLT if the investigator considers it to be clinically relevant and attributed (definitely, probably, or possibly) to the study intervention and meets at least 1 of the DLT criteria. Severity for DLT will be reported according to the NCI-CTCAE v5.0. Up to 4 weeks
Primary Part 2: Number of participants with withdrawals due to AEs during maintenance dosing Up to 36 weeks
Secondary Part 1: Maximum concentration (Cmax) following administration of GSK3745417 Up to 36 weeks
Secondary Part 1: Area under the concentration-time curve AUC(0-t) following administration of GSK3745417 Up to 36 weeks
Secondary Part 1: AUC (0-tau) following administration of GSK3745417 Part 1: AUC(0-infinity) following repeated dose administration of GSK3745417 Up to 36 weeks
Secondary Part 1: AUC(0-infinity) following repeated dose administration of GSK3745417 Up to 36 weeks
Secondary Part 1: AUC(0-infinity) following single dose administration of GSK3745417 Up to 36 weeks
Secondary Part 1: Terminal phase elimination rate constant (Lambda Z) following administration of GSK3745417 Up to 36 weeks
Secondary Part 1: Terminal phase half-life (t1/2) following single dose administration of GSK3745417 Up to 36 weeks
Secondary Part 1: Systemic clearance of parent drug (CL) following administration of GSK3745417 Up to 36 weeks
Secondary Part 1: Volume of distribution (V) following administration of GSK3745417 Up to 36 weeks
Secondary Part 2: Number of participants with AEs, leading to dose modification and dose delays Up to 36 weeks
Secondary Part 2: Number of participants with SAEs and AESIs leading to dose modification and dose delays Up to 49 weeks
Secondary Part 2: Cmax following administration of GSK3745417 Up to 36 weeks
Secondary Part 2: AUC(0-t) following administration of GSK3745417 Up to 36 weeks
Secondary Part 2: AUC (0-tau) following administration of GSK3745417 Up to 36 weeks
Secondary Part 2: AUC(0-infinity) following repeated dose of GSK3745417 Up to 36 weeks
Secondary Part 2: AUC(0-infinity) following administration of single dose GSK3745417 Up to 36 weeks
Secondary Part 2: Lambda Z following administration of GSK3745417 Up to 36 weeks
Secondary Part 2: t1/2 following administration of single dose GSK3745417 Up to 36 weeks
Secondary Part 2: CL following administration of GSK3745417 Up to 36 weeks
Secondary Part 2: V following administration of GSK3745417 Up to 36 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05319587 - Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Active, not recruiting NCT04090736 - Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy Phase 3
Completed NCT01617226 - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS Phase 2
Terminated NCT00957580 - Trial of Pimasertib in Hematological Malignancies Phase 2
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Completed NCT00640796 - Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors Phase 1
Completed NCT00458250 - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H Phase 1
Completed NCT01690624 - BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse Phase 1
Recruiting NCT05471700 - Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients Phase 1/Phase 2
Not yet recruiting NCT05016063 - Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Early Phase 1
Not yet recruiting NCT04450784 - ObServatory Children Acute RElated Therapy Leukemia
Recruiting NCT04265963 - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT04968860 - Oral Health Condition and Quality of Life in Children With Leukemia
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Terminated NCT02841540 - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes Phase 1
Recruiting NCT05453903 - A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Phase 1
Completed NCT03720366 - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients Phase 1
Withdrawn NCT04230564 - Acute Myeloid Leukemia Real World Treatment Patterns
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1
Completed NCT01835587 - Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). Phase 1/Phase 2